Rectal Cancer Clinical Trials

180 recruiting

Rectal Cancer Trials at a Glance

637 actively recruiting trials for rectal cancer are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Phase 2 with 240 trials, with the heaviest enrollment activity in Guangzhou, Houston, and New York. Lead sponsors running rectal cancer studies include Fudan University, Sun Yat-sen University, and National Cancer Institute (NCI).

Browse rectal cancer trials by phase

Treatments under study

About Rectal Cancer Clinical Trials

Looking for clinical trials for Rectal Cancer? There are currently 180 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rectal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rectal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 637 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 1

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Colorectal Cancer MetastaticLung Metastases
University Health Network, Toronto10 enrolled1 locationNCT05611034
Recruiting
Phase 3

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

Rectal CancerRectal Cancer Patients
Shandong Cancer Hospital and Institute210 enrolled1 locationNCT06850090
Recruiting
Phase 1Phase 2

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

Rectal Cancer
Fudan University50 enrolled1 locationNCT07561060
Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting
Phase 3

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Rectal CancerpMMR (Microsatellite Stable Rectal Cancer)
Sun Yat-sen University556 enrolled1 locationNCT07528209
Recruiting
Phase 2

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Rectal Cancer Patients
Sun Yat-sen University88 enrolled1 locationNCT06911684
Recruiting
Phase 2

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
The First Hospital of Jilin University30 enrolled1 locationNCT07559760
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled76 locationsNCT04929223
Recruiting

Clinicopathological Characteristics of Colon Cancer in Young Age

Colo-rectal CancerMolecular Pathway Deregulation
Seoul National University Bundang Hospital1,400 enrolled1 locationNCT05365412
Recruiting
Not Applicable

Pilot Testing of a Colorectal Cancer Education Program

Colorectal Cancer Screening
NYU Langone Health50 enrolled1 locationNCT07361614
Recruiting
Not Applicable

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University47 enrolled1 locationNCT04643041
Recruiting
Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Pancreatic CancerGastric CancerColon Cancer+2 more
National Cancer Institute (NCI)110 enrolled1 locationNCT03190941
Recruiting
Phase 2

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer(SPARKLE)

Unresectable Locally Recurrent Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University31 enrolled1 locationNCT06767007
Recruiting
Not Applicable

Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma

CRC (Colorectal Cancer)CRC Screening
University of Oklahoma150 enrolled1 locationNCT07254910
Recruiting
Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649
Recruiting
Phase 2

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Colorectal Cancer MetastaticAdvanced Colorectal Cancer
Suzhou Teligene Ltd.80 enrolled1 locationNCT06589830